Current Cardiology Reports

, 15:394

INTERMACS and MedaMACS: How Will They Guide Future Therapy?

Congestive Heart Failure (J Lindenfeld, Section Editor)

DOI: 10.1007/s11886-013-0394-y

Cite this article as:
Stewart, G.C. & Stevenson, L.W. Curr Cardiol Rep (2013) 15: 394. doi:10.1007/s11886-013-0394-y
Part of the following topical collections:
  1. Topical Collection on Congestive Heart Failure

Abstract

The INTERMACS registry has played a central role in the evolving field of device therapy for advanced heart failure (HF). This nationwide, prospective registry of approved assist devices has defined the boundaries of mechanical support, tracked the evolution from pulsatile to continuous flow, developed new profiles for advanced HF, and standardized adverse event definitions. INTERMACS has guided current therapy and in the future will do so aided by new insights from MedaMACS, a parallel registry of medically-managed ambulatory patients with advanced HF. Together INTERMACS and MedaMACS will leverage the power of observation research to guide patient-centered decisions about mechanical circulatory support.

Keywords

Heart failureHeart assist devicesCardiomyopathyRegistriesINTERMACSMedaMACSTherapy

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Brigham and Women’s HospitalCenter for Advanced Heart DiseaseBostonUSA